

medicare



Narcolepsy without cataplexy – armodafinil or modafinil – initial authority application

Online PBS Authorities	You do not need to complete this form if you use the Online PBS Authorities system.
	For more information and how to access the Online PBS Authorities system, go to servicesaustralia.gov.au/hppbsauthorities
When to use this form	Use this form to apply for initial PBS-subsidised armodafinil or modafinil for patients with narcolepsy without cataplexy.
Important information	Initial applications to start PBS-subsidised treatment can be made using the Online PBS Authorities system or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.
	Under no circumstances will phone approvals be granted for narcolepsy without cataplexy initial authority applications.
	The information in this form is correct at the time of publishing and may be subject to change.
Continuing treatment	This form is ONLY for initial treatment.
	After an authority application for initial treatment has been approved, applications for continuing or changing treatment can be made in real time using the Online PBS Authorities system or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.
Treatment specifics	Armodafinil and modafinil are not PBS-subsidised when used in combination with each other or with PBS-subsidised dexamfetamine sulfate.
For more information	Go to servicesaustralia.gov.au/healthprofessionals



medicare

PBS

Narcolepsy without cataplexy – armodafinil or modafinil – initial authority application

Online PBS Authorities



You do not need to complete this form if you use the **Online PBS Authorities** system.

Go to servicesaustralia.gov.au/hppbsauthorities

Patient's details

1	Medicare card number
	or
	Department of Veterans' Affairs card number
2	Dr 🗌 Mr 🗌 Mrs 🗌 Miss 🗌 Ms 🗌 Other
	Family name
	First given name
•	
3	Date of birth (DD MM YYYY)
_	
Pr	escriber's details
4	Prescriber number
5	Dr 🗌 Mr 🗌 Mrs 🗌 Miss 🗌 Ms 🗌 Other 📖
	Family name
	Eiret aivon namo
	First given name
6	
6	Business phone number (including area code)
6	Business phone number (including area code)
6	Business phone number (including area code)
6	Business phone number (including area code)

Conditions and criteria

To qualify for PBS authority approval, the following conditions must be met.

7 This application is for:

	armodafinil
or	
	modafinil

8 Is the patient being treated by a qualified sleep medicine practitioner or neurologist?

No	
Yes	

9 Has the patient had excessive daytime sleepiness, recurrent naps or lapses into sleep occurring almost daily for at least 3 months?

No	
Yes	

10 Does the patient have any medical or psychiatric disorder that could otherwise account for the hypersomnia?

No	
Yes	



	patient is unable to receive therapy with dexamfetamine fate for this condition due to:	Privacy notice
Suil	a psychiatric disorder	15 Personal information is protected by law (including the
	a cardiovascular disorder	Privacy Act 1988) and is collected by Services Australia for the
	a history of substance abuse	purposes of assessing and processing this authority application Personal information may be used by Services Australia, or
	glaucoma	given to other parties where the individual has agreed to this,
	any other absolute contraindication as specified in the	where it is required or authorised by law (including for the
	Therapeutic Goods Administration (TGA) approved Product	purpose of research or conducting investigations).
	Information	More information about the way in which Services Australia manages personal information, including our privacy policy, ca
	Provide details of the absolute contraindication posed with dexamfetamine therapy	be found at servicesaustralia.gov.au/privacypolicy
		Prescriber's declaration
		You do not need to sign the declaration if you complete this form
	the development of an inteleronce with a coverity to	using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at
	the development of an intolerance with a severity to necessitate treatment withdrawal	servicesaustralia.gov.au/hpos
	Provide details of the intolerance	16 I declare that:
		 I am aware that this patient must meet the criteria listed i the current Schedule of Pharmaceutical Benefits to be
		eligible for this medicine.
) The	notiont hoo	 I have informed the patient that their personal information (including health information) will be disclosed to Service
	e patient has:	Australia for the purposes of assessing and processing the
	a mean sleep latency \leq 10 minutes on a Multiple Sleep Latency Test (MSLT) with at least 6 hours of sleep prior to	authority application.
	the test	I have provided details of the proposed prescription(s) and
	MSLT result	the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction.
	min	 the information I have provided in this form is complete at
Da	Date of the MSLT (DD MM YYYY)	correct.
	Go to 13	I understand that:
or		giving false or misleading information is a serious offence
	an electroencephalographic (EEG) recording showing the	I have read, understood and agree to the above.
	pathologically rapid development of Rapid Eye Movement	Date (DD MM YYYY) (you must date this declaration)
	(REM) sleep Date of the EEG (DD MM YYYY)	
	Go to 14	Prescriber's signature (only required if returning by post)
2 Hae	the patient had a polysomnography test conducted prior to	
	MSLT test?	<i>L</i>
No		
Yes	s 🕩 Provide details	Returning this form
	Date of the polysomnography test (DD MM YYYY)	Return this form, details of the proposed prescription(s) and any
		relevant attachments:
	Length of sleep (in minutes) prior to the MSLT	• online (no signature required), upload through HPOS at
	(must be at least 360 minutes)	servicesaustralia.gov.au/hpos
	min	Or
		by post (signature required) to Sorvices Australia
Check	list	Services Australia Complex Drugs Programs
4	The relevant attachments need to be provided with	Reply Paid 9826
Ø	this form.	HOBART TAS 7001